HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-Marie Zajac Selected Research

phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamide

2/2016Cholesterol-rich lipid rafts are involved in neuropeptide FF anti-nociceptin/orphanin FQ effect.
5/2014A high-affinity, radioiodinatable neuropeptide FF analogue incorporating a photolabile p-(4-hydroxybenzoyl)phenylalanine.
4/2012GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.
1/2011Neuropeptide FF receptor modulates potassium currents in a dorsal root ganglion cell line.
11/2010Opioid-modulating properties of the neuropeptide FF system.
8/2008Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells.
5/2007Staurosporine differentiation of NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells induces selectivity of NPFF activity towards opioid receptors.
5/2006Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model.
3/2005Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells.
10/2003Identification of proNeuropeptide FFA peptides processed in neuronal and non-neuronal cells and in nervous tissue.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-Marie Zajac Research Topics

Disease

11Neuroblastoma
01/2020 - 10/2003
3Opioid-Related Disorders (Opiate Addiction)
03/2013 - 01/2005
3Pain (Aches)
11/2010 - 12/2002
1Obesity
12/2020
1Substance-Related Disorders (Drug Abuse)
03/2013
1Normal Pressure Hydrocephalus
12/2002

Drug/Important Bio-Agent (IBA)

11phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamideIBA
02/2016 - 12/2002
6Opioid Analgesics (Opioids)IBA
12/2020 - 01/2005
3Peptides (Polypeptides)IBA
05/2014 - 12/2002
2mu Opioid Receptors (mu Opioid Receptor)IBA
01/2020 - 05/2014
2delta Opioid Receptors (delta Opioid Receptor)IBA
05/2006 - 03/2005
1NeuropeptidesIBA
12/2020
1NociceptinIBA
02/2016
1EpitopesIBA
05/2014
13- ((3- cholamidopropyl)dimethylammonium)- 1- propanesulfonate (CHAPS)IBA
05/2014
1Detergents (Detergent)IBA
05/2014
1Heroin (Diamorphine)IBA
03/2013
1Morphine (MS Contin)FDA LinkGeneric
03/2013
1PlasticsIBA
03/2013
1CalciumIBA
04/2012
1Opioid Receptors (Opioid Receptor)IBA
05/2007
1StaurosporineIBA
05/2007
1AmidesIBA
10/2003
1leucyl-phenylalanineIBA
10/2003
1Complementary DNA (cDNA)IBA
10/2003
1alanylphenylalanine (Ala-Phe)IBA
10/2003

Therapy/Procedure

1Analgesia
12/2020
1Self Administration (Administration, Self)
03/2013